1. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours 
M.T. Dillon, Z. Boylan, D. Smith, J. Guevara, K. Mohammed, C. Peckitt, M. Saunders, U. Banerji, G. Clack, S.A. Smith, J.F. Spicer, M.D. Forster, K.J. Harrington 
Clinical and Translational Radiation Oncology 
Volume 12, Pages (August 2018)
DOI: /j.ctro
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1 study design for parts A and B.
Clinical and Translational Radiation Oncology  , 16-20DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 2 study design for part C.
Clinical and Translational Radiation Oncology  , 16-20DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions